A Case of Chronic Schizophrenia Who were Switched from Combined Treatment to Monotherapy and Achieved a Decrease in Positive Symptoms after Lowering the
In this article, a chronic schizophrenic case whose treatment is changed from combination of clozapine with aripiprazole to clozapine monotherapy and whose positive symptoms decreased with the decrease of clozapine doses 900 mg/day to 625 mg/day is reported.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:A case of chronic schizophrenia who were switched from combined treatment to monotherapy and achieved a decrease in positive symptoms after lowering the clozapine dose Despite the limited evidence to support the combination of antipsychotics in treatment resistant schizophrenia in the literature, this situation is common in clinical practice.
📊
Key Findings & Data:Treatment guidelines recommend monotherapy for schizophrenia primarily.
💡
Conclusion & Impact:In this article, a chronic schizophrenic case whose treatment is changed from combination of clozapine with aripiprazole to clozapine monotherapy and whose positive symptoms decreased with the decrease of clozapine doses 900 mg/day to 625 mg/day is reported.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
A case of chronic schizophrenia who were switched from combined treatment to monotherapy and achieved a decrease in positive symptoms after lowering the clozapine dose Despite the limited evidence to support the combination of antipsychotics in treatment resistant schizophrenia in the literature, this situation is common in clinical practice. Treatment guidelines recommend monotherapy for schizophrenia primarily. In this article, a chronic schizophrenic case whose treatment is changed from combination of clozapine with aripiprazole to clozapine monotherapy and whose positive symptoms decreased with the decrease of clozapine doses 900 mg/day to 625 mg/day is reported.
🔖
Cite This Article
HAMURCU, H. D., CAYKOYLU, A., PEKSEN, E., OZTURK, M., SEVİL, N. (2022). A Case of Chronic Schizophrenia Who were Switched from Combined Treatment to Monotherapy and Achieved a Decrease in Positive Symptoms after Lowering the. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 3, 324–328. https://ajindex.com/articles/573903
Altinyazar V, Yuksel N. Combination treatments in schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2011;21(4):368-80. (Turkish
Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2009;42(2):66-71. [CrossRef] 3. Albayrak-Ozalmete O, Ceylan ME, Ozalmete O, Efe-Sevim M. Antipsychotic polypharmacy in schizophrenic inpatients. Archives of Neuropsychiatry 2010;47(1):23-8
Boke O, Sarisoy G, Akbas S, Aker S, Korkmaz S, Aker AA, Bahce Z, Celik C, Sahin AR. Combined antipyschotic prescription for inpatients: A retrospective study. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2006;16(3):167-73. (Turkish
Anil AE, Turgut IT, Rezaki M, Gogus A. A review on augmentation of clozapine treatment. Turk Psikiyatri Derg 2002;13(1):65-77. (Turkish 6. Ozalmete OA, Ozalmete EO, Ceylan ME, Sevim ME. Causes of antipsychotic polypharmacy in schizophrenia treatment. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2009;19(1):68-74. (Turkish
Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother. 2003;37(7-8):951-5. [CrossRef 8. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161(4):700-6. [CrossRef] 9. Mossaheb N, Kaufmann RM. Role of aripiprazol in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2012;8:235-44. [CrossRef] 10. Fleischhacker WW, Heikkinen ME, Olié JP, Landsberg W, Dewaele P, McQuade RD, et al. Effects of adjunctive treatment with aripirazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13(8):1115-25. [CrossRef] 11. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994;55 (Suppl. B):S153-S6
Pacia SV, Devinsky O. Clozapine-related seizures:experience with 5,629 patients. Neurology 1994;44(12):2247-9. [CrossRef] 13. Fujimori S, Yoneda Y. Neuropsychiatric disorders and GABA. Nihon Shinkei Seishin Yakurigaku Zasshi 2004;24(5):265-71
Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about sch